
Sunil Dogra
Articles
-
1 month ago |
tandfonline.com | Sunil Dogra |Sukhdeep Singh
ABSTRACTIntroduction- Sonelokimab, a bispecific nanobody targeting interleukins (IL)-17A and IL-17F, has emerged as a novel therapeutic candidate for chronic inflammatory diseases such as psoriasis, hidradenitis suppurativa (HS), and psoriatic arthritis. Its innovative design offers improved tissue penetration, rapid clearance, and reduced immunogenicity, addressing limitations of current monoclonal antibody therapies.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →